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Abstract
Skin cancer is a growing public health problem. Early and accurate detection is important, since prognosis and cost of treatment
are highly dependent on cancer stage at detection. However, access to specialized health care professionals is not always
straightforward, and population screening programs are unlikely to become implemented. Furthermore, there is a wide margin
for improving the efficiency of skin cancer diagnostics. Specifically, the diagnostic accuracy of general practitioners and family
physicians in differentiating benign and malignant skin tumors is relatively low. Both access to care and diagnostic accuracy fuel
interest in developing smartphone apps equipped with algorithms for image analyses of suspicious lesions to detect skin cancer.
Based on a recent review, seven smartphone apps claim to perform image analysis for skin cancer detection, but as of October
2018, only three seemed to be active. These apps have been criticized in the past due to their lack of diagnostic accuracy. Here,
we review the development of the SkinVision smartphone app, which has more than 900,000 users worldwide. The latest version
of the SkinVision app (October 2018) has a 95% sensitivity (78% specificity) for detection of skin cancer. The current accuracy
of the algorithm may warrant the use of this app as an aid by lay users or general practitioners. Nonetheless, for mobile health
apps to become broadly accepted, further research is needed on their health impact on the health system and the user population.
Ultimately, mobile health apps could become a powerful tool to reduce health care costs related to skin cancer management and
minimize the morbidity of skin cancer in the population.
(JMIR Dermatol 2019;2(1):e13376)  doi: 10.2196/13376
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Rationale for Using Mobile Health Apps
for Early Detection of Skin Cancer
There are three main types of skin cancers—malignant
melanoma (MM), squamous cell carcinoma (SCC), and basal
cell carcinoma (BCC)—with the latter two also known as
keratinocyte carcinoma (KC). In the United States, it was
estimated that about 91,000 people will be diagnosed with
melanoma and 9300 will die due to MM in 2018 [1]; in addition,
in 2012, more than 5 million people were diagnosed and 3
million received treatment for KC, which is more than the values
for all other cancers combined [2]. Globally, in 2015, there were
about 351,000 new incident melanoma cases and 60,000
melanoma-related deaths [3], with the highest burden of disease
in Australasia, North America, and Europe. In the last 30 years,
the incidence of MM, adjusted for changes in the age distribution
of the population, more than doubled in the United States
(among Caucasians) and the United Kingdom; nearly doubled
in Norway, Sweden, and New Zealand; and increased by
approximately 75% in Australia [4]. This is mostly due to
changes in risk factors such as increased exposure to ultraviolet
light and indoor tanning [4-6]. Since these risk factors are mostly
preventable, comprehensive prevention programs aimed at better
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sun protection behavior have been implemented in several
countries, such as SunSmart in Australia [7].
Although several organizations have issued recommendations
on how often to check skin lesions for individuals at higher risk
(eg, Fitzpatrick scale I-III, a family history of melanoma, a
history of sun-damaged skin, and multiple atypical nevi),
ranging from every 3 months to every year [8], most countries
do not have an organized early detection program for skin
cancer. The US Preventive Services Task Force has issued an
I-recommendation for skin cancer screening [9], indicating that
there is insufficient evidence to evaluate the harms and benefits
of skin cancer screening. Currently, there are only two major
skin screening programs: (1) In the United States, the American
Academy of Dermatology, which started in 1985, includes
screening and skin cancer awareness education [10] and (2) in
Germany, a national screening program was started in 2008
[11]; the program in Germany does not seem to be effective in
reducing skin cancer–related mortality and morbidity [12].
In practice, it is difficult to provide a high-quality skin checks,
even for high-risk individuals. Waiting times and, in some areas,
dermatologist shortages, out-of-pocket costs, and distance to
the nearest dermatologist [13] may discourage people at risk
from receiving dermatological care. For example, in the United
States, a study found that availability of a dermatologist within
the county is associated with a 35% decrease in melanoma
mortality [14]. Another US estimate found that only a quarter
of individuals at higher risk of skin cancer have ever received
a total skin body examination [8].
In several countries, namely, in the United Kingdom and the
Netherlands, skin checks are first carried out by a general
practitioner (GP, also sometimes referred to as primary care
provider), who may then choose to refer a patient to a
dermatologist if there is a suspicion of skin cancer. However,
several studies suggest that the accuracy of GPs to detect skin
cancer is relatively low [15-20]. The sensitivity of GPs without
specific training to detect skin cancer was estimated to be below
60% in British and Dutch studies [15,16]. One US study found
that only 35% of patients had a correct diagnosis [17].
Altogether, this may result in a delay in diagnosis or missing
the cancer in its earlier stages when patient survival is more
favorable and treatment is less costly. Furthermore, many GP
consultations and subsequent referrals to a specialist to examine
the skin for cancer result in a benign diagnosis. A Dutch study
found that 69% of GP consultations related to suspicious skin
lesions result in a benign diagnosis [19], and two separate studies
in the Netherlands estimated that a large proportion (40%) of
referral cases to the dermatologist due to suspicion of skin
cancer turned out to be benign cases [19,20]. Two studies (in
the United States and Germany) including more than 70
dermatologists found that dermatologists’ disease classification
decisions have a specificity of 60%-80% [21,22], which may
result in unnecessary biopsies/excisions.
Early detection and surveillance of skin cancer could be more
efficient with mobile health (mHealth) apps, which are easily
accessible due to the ubiquity of smartphone usage. One
example of a smartphone app for self-assessment of skin lesions
for skin cancer is the SkinVision app (SVA), developed by
SkinVision, BV, The Netherlands). In the next section, we
review the development of SkinVision app over time.
Development of a Smartphone App for
Skin Cancer Detection
SkinVision is a smartphone app built as a digital dermatology
service for self-monitoring skin lesions. It was launched in 2011
and as of October 2018, it was on its fifth major version. The
workflow of the app is given in Figure 1.
Figure 1. Workflow of the SkinVision app service. SVA: SkinVision app.
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A user can self-assess the risk of a skin lesion for skin cancer
by taking a photo with his/her smartphone, which is processed
by an algorithm. The outcome of the procedure is a binary risk
rating, which can be low or high. This smartphone app does not
provide a diagnosis (eg, “you have melanoma”). For high-risk
cases, the user receives advice from the costumer care team
based on the image assessment of an in-house dermatologist.
Development of the SkinVision App
Service
The history of the SkinVision app service is shown in Table 1.
It went through several upgrades throughout its history,
modifying the camera, the algorithm and its evaluation, type of
lesions analyzed, and communication of the algorithm result to
its user. One of the major initial challenges was related to image
acquisition. In the beginning, there was no filter on the images
sent for analyses, which meant that a significant proportion of
the pictures taken by users was of insufficient quality to be
analyzed by the disease classification algorithm or did not even
contain a lesion to be analyzed. Since version 3 of the
SkinVision app (2014), a special camera module [23] has been
embedded, which only lets the camera take a photo after certain
minimal quality conditions are met. Compared to unfiltered
images taken with a standard smartphone camera, the camera
module reduces the number of blurry photos by about 52% on
an average (determined using 2018 data). Altogether,
improvements in the camera module (namely, image quality
checks) and the algorithm pipeline led to a reduction in the
number of assessments that failed to produce a risk rating, from
26% in 2016 to 2% in 2018 on an average.
An overview of studies on the diagnostic accuracy of the
SkinVision app is shown in Table 2. Diagnostic accuracy is
evaluated based on two measures: sensitivity (proportion of
lesions correctly classified as high risk) and specificity (the
proportion of lesions correctly rated as benign). The first
algorithm for skin lesion assessment was a rule-based fractal
algorithm [24]. Initially, it was focused on pigmented skin
lesions and only able to analyze whether MM was present in
the lesion, and it was tested based on clinical review of images.
The Munich University Hospital study was the first
peer-reviewed publication where the SkinVision app algorithm
was evaluated against histopathology [24], and thereafter, the
algorithm achieved 73% sensitivity (83% specificity). During
the Catharina Hospital Eindhoven study [25], the algorithm was
recalibrated to analyze pigmented and nonpigmented lesions.
Currently, it can detect several types of skin cancer (MM, SCC,
and BCC) and skin conditions that can lead to skin cancer,
namely, actinic keratosis and Bowen disease. It achieved 80%
sensitivity (78% specificity) after inclusion of user clinical
information. Although in the Eindhoven study, only 233 lesions
were used for calibration, in 2018, the SkinVision app assembled
a training dataset of more than 130,000 images that were risk
classified by a dermatologist from the app’s user database. This
led to replacement of the rule-based classification algorithm by
a machine learning approach (A Udrea et al, PhD, unpublished
material, 2019).
Table 1. Development of the SkinVision smartphone app.
TestingType of skin cancer
detected
Type of skin lesionCameraAlgorithmLaunch dateVersion
Preclinical testing using
600 images against the
opinion of two dermatol-
ogists
Malignant melanomaPigmented skin lesion
only
Standard smartphone
camera
Rule-based fractal al-
gorithm version 1
May 20111
Preclinical testing using
600 images against the
opinion of two dermatol-
ogists
Malignant melanomaPigmented skin lesion
only
Standard smartphone
camera, exclusion cri-
teria introduced
Rule-based fractal al-
gorithm version 2
December
2012
2
Clinical study, Munich
University Hospital
Malignant melanomaPigmented skin lesion
only
Camera module: exclu-
sion criteria automat-
ed
Rule-based fractal al-
gorithm version 2
September
2014
3
Clinical study, Catharina
Hospital Eindhoven
(more types of skin can-
cer)
Malignant melanoma,
squamous cell carcino-
ma, basal cell carcino-
ma, some premalig-
nant lesions
Pigmented and nonpig-
mented skin lesions
Camera module ver-
sion 1
Rule-based fractal al-
gorithm version 3, all
outcomes checked by
dermatologists (Sept
2016)
July 20164
Data from previous clini-
cal studies and user
database with new algo-
rithm
Malignant melanoma,
squamous cell carcino-
ma, basal cell carcino-
ma, some premalig-
nant lesions
Pigmented and nonpig-
mented skin lesions
Camera module major
version 2a
Machine learning algo-
rithm for image pro-
cessing and classifica-
tion
January
2018
5
aNew features include a dynamic grey threshold to differentiate between normal skin and lesion and a feature that prevents taking pictures without
uniform luminosity.
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Table 2. Studies on the accuracy of the SkinVision app’s risk assessment. All studies presented here were sponsored by the SkinVision app.
RemarksSpecificity (%)Sensitivity (%)Test setAlgorithmDataStudy
Algorithm tested only
on malignant melanoma
837326 lesions with
melanoma
Rule-based fractal al-
gorithm version 2
University Hospital
Munich
Maier et al,
2014 [24]
Algorithm tested mostly
on keratinocyte carcino-
ma (Munich data also
used for testing)
78a80a108 lesions including
several types of skin
cancer
Rule-based fractal al-
gorithm version 3
Catharina Hospital
Eindhoven
Thissen et al,
2017 [25]
All types of skin cancer7895285 lesions with skin
cancer, from clinical
studies and a user
database with
histopathology infor-
mation
Machine learn-
ing–based algorithm
Clinical studies and
SkinVision app user
database
Udrea et al,
2019b
aAfter incorporating answers into a questionnaire about the skin lesion.
bManuscript under peer review (June 2019). For more details on these results, see Multimedia Appendix 1.
SkinVision App Service in 2018
Camera
Before downloading the app, the smartphone should be equipped
with a camera capable of producing a video stream with
sufficiently high resolution. Although the app uses a regular
smartphone camera, the camera module embedded in the app
automatically places some restrictions to ensure minimal quality
requirements of the images are met: The image needs to be
focused, the lesion should be present and contained in the image,
and there should be no hair or shadows covering the lesion. The
module also prevents the camera from taking images that cannot
be assessed by the algorithm (eg, lesions under a nail or near
clothing in a skin fold).
Algorithm for Lesion Assessment
There are several steps to analyze the lesion. The first task of
the algorithm is to identify and separate the lesion from normal
skin. This is done using a machine learning technique called
conditional Generative Adversarial Neural Network [26] (A
Udrea et al, PhD, unpublished material, 2019). After the lesion
is segmented, all “noise” (eg, hair surrounding the lesion) is
removed in the image by applying an inpainting procedure [27].
The third step is to extract the features from the lesion that are
used in the disease classification algorithm. These features
include 24 shape, color, and texture attributes that characterize
the lesion. A Support Vector Machines (SVM) classifier is used
to provide a risk rating, which can be high or low. The SVM
model is obtained by maximizing sensitivity to detect cancer
subject to a constraint of a minimal specificity value (eg, 80%).
The optimization is performed using a Particle Swarm
Optimization algorithm [28]. The classification algorithm is
regularly updated and retrained with new data. This is necessary
to maintain robustness to variation due to imaging, newer
devices, and the user population adopting the app.
Training and Testing
For training of the algorithm, we used images obtained from
the user database (more than 130,000 pictures from 30,000
users), which received either a low- or high-risk tag during
quality control of the algorithm by a dermatologist affiliated
with SkinVision. A selection of cases clinically validated as
low risk were randomly selected from the user database, while
all cases rated as high risk or with a histopathological report
were used, since there were considerably fewer of them. For
testing the sensitivity, we used 285 skin lesions derived from
both previous clinical studies (Munich and Catharina Hospital,
195 skin lesions, containing most common forms of skin cancer)
and the user database (90 cases of melanoma that received
histopathological confirmation from users). Furthermore, to test
the specificity, we used 6000 randomly selected cases from the
user database (June to August 2018), which were tagged as
benign by SkinVision-affiliated dermatologists and were not
used in training. An overview of these datasets together with
the participant flowcharts are shown in Multimedia Appendix
1.
Performance Evaluation
The gold standard (main comparator) to evaluate algorithm
sensitivity is comparison against histopathologically validated
cancers. The second comparator is the performance of the
algorithm against the image assessment of the dermatologist
(which is comparable to a teledermatology consult). In order to
calculate the specificity, we use images of lesions that were
classified by dermatologists as benign cases, since these are not
usually biopsied, and therefore, there is no histopathology report.
Sensitivity has improved from 73% in the first peer-reviewed
study, where only MM was detectable, to 95% in the current
version of the algorithm (78% specificity), where the SkinVision
app can detect all forms of skin cancer (Table 2 and Multimedia
Appendix 1).
Postassessment Follow-Up
Since 2016, images processed by the algorithm are reviewed
by at least one affiliated dermatologist. To help users with the
interpretation of high-risk cases, a senior dermatologist adds
advice depending on the probable severity of the disease. The
advice can contain the labels “Show,” “Visit,” or “Urgent.”
“Show” indicates that the lesion should be shown at the next
planned doctor appointment, “Visit” indicates that the
appointment should be made soon, and “Urgent” advises the
user to show the lesion to a doctor as soon as possible. Users
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with a low-risk rating only receive a reminder to check their
skin regularly.
Assessments with a high-risk rating given by the dermatologist
are followed up by the customer support department of the
SkinVision app. If the user does not respond, he/she may receive
additional messages encouraging a visit to the doctor, depending
on the perceived severity of the disease. Some users share their
diagnosis of skin cancer with the SkinVision app (n=3806,
Multimedia Appendix 1). Of these, a small proportion
(338/3806, 8.8%) share the histopathology report. At the end
of September 2018, about 338 users had shared histopathological
reports, of which 58% (178/338) were of MM diagnosis. The
histopathologically validated cases are used for training and
testing the algorithm.
Smartphone App Users
In Table 3, we show self-reported demographic data on
SkinVision app users. As of September 2018, the SkinVision
app has performed more than 1.8 million assessments. Some of
these users shared their demographic data with the SkinVision
app: 56% (355,491/635,807) shared their age group and 28.5%
(181,706/635,807) shared their gender. Although skin cancer
is more prevalent in older age groups, only 7% of the people
were older than 60 years of age (19,358/355,491) in the user
database and about 31% (110,529/355,491) were younger than
30 years of age. More than 60% of the users were female
(118,182/181,706). A majority of the users come from the
following countries: The Netherlands (n=111,063, 17.4%),
United Kingdom (n=109,178, 17.2%), Australia (n=109,126,
17.2%), New Zealand (n=70,244, 11%), and Belgium (n=21,328,
3.3%).
Table 3. Self-reported demographic characteristics of the SkinVision app users. The data are from the SkinVision app proprietary user database,
accessed in September 2018. Numbers are based on users, who made a picture that was evaluated by the algorithm, and filled the online questionnaire.
UsersCharacteristic
931,789Number of registered users
635,807aTotal number of users with an assessment
Genderb, n (%)
62,914 (9.9)Male 
118,182 (18.6)Female 
454,731 (71.5)Missing 
Age groupb (years), n (%)
110,529 (17.4)<30 
98,327 (15.5)30-39 
74,928 (11.8)40-49 
46,840 (7.4)50-59 
19,358 (3.0)60-69 
5509 (0.9)>70 
280,316 (44.0)Missing 
Country, n (%)
111,063 (17.4)The Netherlands 
109,178 (17.2)Australia 
109,126 (17.2)United Kingdom 
70,244 (11.0)New Zealand 
21,128 (3.3)Belgium 
215,355 (33.9)Others 
aSome users may be health care providers taking pictures of multiple patients, so this is likely an underestimate.
bFor the gender and age categories, about 75% and 44%, respectively, did not fill any data.
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State of the Field
Available Mobile Health Apps for Skin Cancer
Detection
A recent review [29] found that there are 43 smartphone apps
developed for skin cancer detection, monitoring, and education.
Of these, nine smartphone apps use an algorithm for image
analysis [29]. We verified the current status of these smartphone
apps in December 2018 with Google search and PubMed and
in app stores. The results are presented in Table 4. We confirm
that seven apps claim to use an algorithm for image analysis.
Of these, four do not seem to be active as of October 2018.
Compared to a previous review conducted in July 2014 [30],
there are now less apps available for risk assessment of skin
lesions through image analysis (three instead of four).
Table 4. List of smartphone apps that claim to perform skin lesion image analyses to detect skin cancer, based on a systematic review [29].a
SourcecStatusEvidence on PubMedAlgorithmbCommercial name
[31]Removed from app store, last
update on January 2017
Not foundMachine learningDermaCompare
[32,33]Removed from app store, last
update on February 2015
Yes, one supported peer-re-
viewed publicationd
Content-based image retrieval,
k-nearest neighbor
Lubax
[34]Removed from app store, up-
date on February 2016
Not found; there is a conference
abstract only
Grab cut algorithm (segmenta-
tion) and SVMf (classification)
MSkinDoctore
[35]Removed from app store, last
update on September 2016
Not foundMachine learningMySkinMap
[36]AvailableUncleargImage processing techniques,
ABCDE rule
SkinScan
[23-25,37], A Udrea et
al, PhD, unpublished
material, 2019
AvailableYes, two supported peer-re-
viewed publications, evaluated
in independent publications
Conditional generative adversar-
ial neural network (segmenta-
tion) and SVM (classification)
SkinVision
[38]AvailablehYes, evaluated in independent
publications
Image processing techniques,
ABCDE rule
SpotMole
aAfter verifying the websites of every app (if available), it seems that two of the apps mentioned in the Ngoo et al study [29] with commercial
names—Myskinpal and Skin Prevention - Photo Body—do not claim to perform automated image analysis for risk assessment. They only store images
of moles to track changes.
bIf available, the information is retrieved from scientific publications; otherwise, it is collected from the company’s own website or app store description.
cAccessed on Dec 12, 2018.
dResults obtained in this publication [32] only for melanomas and large lesions.
eThere is another app available with the same name; however, that one does not perform image analyses.
fSVM: support vector machines.
gThere is an associated reference to an app of the same name from 2011; however, this does not appear to be the same app.
hThis smartphone app has a website (spotmole.com); however, it was offline at the last time of access (Dec 12, 2018). It is unclear if this project is still
alive, given the fact that the last update was in March 2016 and that it seems this app is being developed by a single individual.
Comparison of the SkinVision App With Other Apps
Currently, there seem to be three apps available for detection
of skin cancer, including SkinVision app, SpotMole, and
skinScan. All three allow the user to take a picture with the
smartphone camera. The SkinVision app algorithm is based on
machine learning techniques, while SpotMole and skinScan use
algorithms inspired by the ABCDE rule [39]. The SkinVision
app involves quality control by a dermatologist; however, the
other apps do not seem to offer any further follow-up or advice
to users.
Tables 2 and 5 show the diagnostic accuracy results from recent
publications. We found five peer-reviewed studies and one
submitted study about two available mHealth apps and two
mHealth apps that do not exist anymore. Of the three currently
available apps, no diagnostic accuracy or other studies were
found for skinScan. The other two smartphone apps were
evaluated in at least one study [40], and only one app (ie,
SkinVision app) [24,25] has published evidence to show whether
their proprietary algorithm is accurate.
mHealth apps for skin cancer assessment (including SkinVision
app) have been criticized in past studies [40,41], because their
accuracy was found to be significantly lower than that of a
dermatologist. In Tables 2 and 5, only three studies showed a
diagnostic accuracy close to that of a dermatologist, and one of
these studies [32] only showed a high accuracy for large
melanoma lesions. Although some of these studies are recent,
these findings are possibly already outdated, as this is a rapidly
evolving field. These results could also be explained by the
limited sample size, including too few skin cancer cases and
selected samples, which may be inadequate to calculate
sensitivity or specificity or, in the case of SkinVision app,
nonutilization of the full service with the dermatologists’ advice.
Overall, the amount of evidence on the diagnostic accuracy of
smartphone apps is still scarce, as there are few mHealth apps
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providing this service. It is also difficult to make an accurate
comparison between different apps, since the rate of service or
algorithm change is faster than the process of peer-review
publication. It could also be the case that some developers may
choose to publish their results in sources that are not referenced
in PubMed, namely, ArXiv. An illustrative example of these
difficulties is a Cochrane review [42] published in December
2018 on the diagnostic accuracy of smartphone apps, which
only found two studies but only included articles published
before August 2016, making it possibly obsolete at the time of
publication. For these reasons, one should be cautious when
interpreting the available literature.
Table 5. Recent studies on the diagnostic accuracy of smartphone apps for risk assessment of skin lesions.
RemarksSpecificity (95%
CI)
Sensitivity (95%
CI)
Test SetAlgorithmLocation for data
collection
App, study, year
Only 1 malignant
melanoma was
found
iOS: 50% (22-
78), Android:
27% (1-56)b
iOS: 57% (41-
73), Android:
72% (58-87)b
1 malignant
melanoma, 41 clini-
cally suspicious le-
sionsa
Rule-based fractal
algorithm version 2
Princess Alexandra
Hospital, Brisbane
SkinVision app,
Ngoo et al, 2018
[40]
Only 1 malignant
melanoma was
found
80% (60-100)43% (28-58)1 malignant
melanoma, 41 clini-
cally suspicious le-
sionsa
Algorithm based on
the ABCDE rule
Princess Alexandra
Hospital, Brisbane
SpotMole, Ngoo et
al, 2018 [40]
Only 1 malignant
melanoma was
found
100% (100-100)21% (9-34)1 malignant
melanoma, 41 clini-
cally suspicious le-
sionsa
Algorithm based on
the ABCDE rule
Princess Alexandra
Hospital, Brisbane
Dr Mole, Ngoo et
al, 2018 [40]
Algorithm tested on-
ly on malignant
melanoma (large le-
sions only)
92% (85-95)90% (86-94)208 lesions with
melanomad
Content-based im-
age retrieval
DermNetNZ, New
Zealand, and Los
Angelesc
Lubax, Cheng et
al, 2015 [32]
Algorithm tested on-
ly on malignant
melanoma
9% (0-41)80% (52-96)9 malignant
melanomas
Not reportedGalway University
Hospital
Not reported, Do-
rairaj et al, 2017
[41]e
aAll lesions had a benign final histopathology diagnosis with the exception of one melanoma in situ.
bNgoo et al 2017 [40] reported the results per type of operating system: iOS/Android.
cDermNetZN is a publicly accessible skin lesion image database from New Zealand containing about 20,000 images. Images collected within the Los
Angeles county were collected by the app company. No reference to a clinical site of the data collection was given in the publication.
dAlgorithm was only tested on “large lesions” defined as melanomas with a diameter ≥10 mm.
eDespite the study being published in 2017, the study took place in 2012.
Improving the Diagnostic Accuracy of Mobile Health
Apps
A promising avenue to improve the diagnostic accuracy of
mHealth apps is to train machine learning algorithms on large
databases of skin cancer images. Several algorithms for skin
cancer classification were recently developed based on clinical
or dermoscopic images, with algorithm accuracy routinely on
par with a dermatologist [21,22,43]. For mHealth apps, the task
of skin lesion classification is more difficult, as the images are
taken by the users themselves, with variability in angle,
luminosity, and smartphone model. The SkinVision app showed
that skin lesion classification based on smartphone images can
also achieve high accuracy (Table 2; A Udrea et al, PhD,
unpublished material, 2019).
Alternatives to Mobile Health Apps
Early detection of skin cancer could be significantly improved
by launching a population screening program, but this is unlikely
to become common due to the high costs and lack of evidence
on harms and benefits [9,44]. As the main risk factors for skin
cancer like indoor tanning or ultraviolet exposure are, in large
part, preventable [45], primary prevention and awareness
campaigns (eg, Melanoma Monday and SunSmart in Australia)
could have a better cost-benefit ratio than early detection [46].
These campaigns are a way for the general public to proactively
adopt preventive behaviors and possibly learn how to recognize
suspicious skin lesions [7]; they seemed to have resulted in
better sun protection behavior [47]. On the other hand, this
success can be reversed if these awareness efforts are not
continuous [47] and they do not solve the shortages or
difficulties in access to high-quality skin checks.
Training GPs or nurses with a special interest in recognizing
skin cancer increases the capacity for early and accurate
detection. However, compared to mHealth apps, it still requires
face-to-face contact, and it is likely not enough to address all
needs [13,48]. Store-and-forward teledermatology [49] allows
users to take a photo and have it analyzed remotely by a
dermatologist. This may solve some of the problems with access
to care, but is solely based on a clinical assessment of a health
care professional and is thus not automated. Smartphone apps
with good performance are likely to be more efficient and could
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lead to larger cost savings for the health system compared to
the above mentioned alternatives.
Usability Risks of Smartphone Apps
Smartphone apps pose some risks for the user, specifically, if
the algorithm returns a negative result while the user has cancer,
and detection and treatment of skin cancer are delayed. It is
very challenging to study the rate of false-negatives due to a
lack of histological verification. The user may also fail to assess
all relevant skin lesions, in particular, if they are located in
places that are hard to reach or that the user cannot see. Given
that the specificity of SkinVision app is about 80%, there will
be a few false-positive cases. This may cause unnecessary stress
on users or unnecessary visits to the GP/dermatologist. Finally,
the user may not follow the advice given in the smartphone app
due to a lack of trust or unawareness.
Evaluating the Health Impact of Mobile
Health Apps
Impact of Mobile Health Apps on Health Care Costs
A Dutch study based on national claims data observed an
increase of about 67% in skin cancer–related costs between
2007 and 2017 (E. Noels, MD, unpublished data, 2019). This
is due to higher costs of skin cancer treatments, for example,
newly available expensive targeted immunotherapies for
late-stage melanomas and, to a lesser extent, due to an increase
in the skin cancer incidence. mHealth apps for self-assessment
of skin lesions could limit this cost increase by (1) by detecting
cancers early, which will reduce the average cost of treatment
(ie, less advanced disease) and recovery and (2) reducing the
need for doctor visits, since many primary care (GP)–related
consultations either result in a benign diagnosis or in referrals
to a specialist of cases that are later diagnosed as benign [19].
Impact of Mobile Health Apps on Public Health
Easy access to a high-quality assessment of skin lesions may
lead to detection of skin cancers at an earlier stage, when their
prognosis and treatment are more favorable. On the other hand,
this could also cause overdiagnosis and overtreatment. Currently,
evidence on the benefits and harms of skin cancer screening is
insufficient [9,44]. To date, there are no randomized skin cancer
screening trials, and it is unlikely that there will be new trials
launched in the near future, since they would require a
substantial number of patients and a long follow-up and it would
be difficult and possibly unethical to guarantee that people in
the control group would not access skin cancer detection
methods. Consequently, it is difficult to determine whether early
detection of skin cancer reduces skin cancer specific mortality.
Another important target outcome could be the incidence of
advanced melanoma. Therefore, indirect evidence on harms and
benefits could be obtained by comparing the stage distribution
of cancers detected early with a smartphone app from national
registries.
Implementation of Mobile Health Apps in the Health
System
The health impact of mHealth apps also depends on where it is
implemented, that is, whether it is restricted to health care
professionals such as GPs or dermatologists or accessible to the
lay population. Offering apps directly to lay users could result
in significantly greater efficiency gains for the health system;
however, some regulatory bodies may prefer to restrict the usage
to health care professionals to minimize usability risks. The
regulatory framework is evolving quickly, with the National
Institute for Health and Care Excellence in the United Kingdom
suggesting a comprehensive approach to regulate mHealth
technologies, taking into account not only the safety and efficacy
of the app, which can be shown by carrying out a diagnostic
accuracy study, but also whether it can plausibly improve current
health care pathways, acceptability with users, and
cost-effectiveness compared to usual care [50].
Barriers to Access of Mobile Health Apps
After implementation, the health impact of mHealth apps will
also depend on the persistence of barriers to adoption among
users (either lay persons or care providers). Zhao et al [51]
described a technology acceptance model for mobile health
[51]. For lay users, age can play a role in the rate of adoption
[51]. Middle-aged and older users (the ones who are at a higher
risk of skin cancer) may give more importance to the perceived
amount of effort needed to learn how to use the smartphone app
and the perceived personal risk for skin cancer. For clinicians,
we believe the perceived ease of use also plays an important
role, since clinicians have a limited amount of time. Other
important factors may include perceived usefulness and efficacy
of the smartphone apps, namely, whether clinicians believe in
the quality of the app and whether they believe it provides the
necessary information to make a clinical decision.
Postmarket Surveillance of Mobile Health Apps
A key point for mHealth apps for skin cancer detection consists
of performing appropriate market surveillance activities in order
to minimize usability risks, since data based on clinical studies
in a controlled setting are likely not sufficient to control for
differences in image-taking behavior or characteristics of the
smartphone model. Algorithms used in mHealth apps should
then be updated periodically, given the feedback from its users,
whether they are lay users or clinicians. It is not easy to have
complete follow-up from users, since due to privacy reasons,
it is not straightforward for the smartphone apps to obtain access
to the final clinical or histopathological diagnosis after the lesion
is assessed by the algorithm.
Future Research
Research is still needed to establish the societal value of
mHealth apps. First, there remains a need for more high-quality
studies on their diagnostic accuracy in different populations.
Second, given that these smartphone apps are accurate enough
to be used by laypersons and GPs, its health and cost effects
are yet to be evaluated.
The impact on the health system in terms of cost reduction due
to less skin lesion–related visits still needs to be tested, ideally
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with a randomized control trial (RCT) accompanied by a
cost-effectiveness analysis. However, performing an RCT may
prove difficult. To design a trial capable of detecting a difference
in the number of doctor visits, the sample size needed to carry
out such a study is in the thousands, as shown by the Dutch data
from 2010 [52] suggesting that about 93 consultations for every
1000 patients are related to skin cancer. The main problem is
that this type of RCT has a high risk of contamination in the
control group (no smartphone app), since access to smartphone
apps and their usage is relatively simple. An alternative solution
could be to follow a quasi-experimental approach for the design
of the study [53].
In the absence of large RCTs and long-term follow-up data,
modelling could be used to estimate the harms and benefits of
early detection of skin cancer. There are a few studies in the
literature that modelled the incidence and mortality of skin
cancer [54-56]. The main drawback of these modelling studies
is the difficulty in estimating tumor onset and progression. This
could be addressed by forming a coalition of multiple modelling
groups for skin cancer, like the Cancer Intervention and
Surveillance Modelling Network (CISNET) group has done for
other cancer sites [57].
Summary and Conclusions
Given the difficulties in access to high-quality care for early
detection of skin cancer, there is considerable interest in
developing algorithms and apps for skin cancer lesion
assessment. Although mHealth apps have been criticized in the
past due to their poor accuracy, the SkinVision app has a high
accuracy to evaluate the risk of skin lesions for skin cancer.
This was achieved due to improvements in the processing of
images taken with the smartphone camera and a large
risk-labeled image database from users, which was used to train
a machine learning algorithm.
However, there are still many open questions regarding the
usage of mHealth apps. National health authorities need to
decide where to position these apps in the health care system
(lay population, GPs, or dermatologists). Health effects of early
and more accurate detection are difficult to estimate. There is
currently no high-quality evidence on the health and cost
benefits and harms of early detection of skin cancer, namely,
on the trade-off between doctor visits and lives saved/advanced
cases avoided. The reduction of the skin cancer burden on the
health system and in the population could be substantial, as
earlier detection of skin cancer could result in a lower average
cost of treatment and a reduction in the number of doctor visits.
However, further studies are needed to confirm this.
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